SIBN logo

SI-BONE, Inc. Stock Price

NasdaqGM:SIBN Community·US$883.4m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

SIBN Share Price Performance

US$20.36
6.65 (48.50%)
US$23.00
Fair Value
US$20.36
6.65 (48.50%)
11.5% undervalued intrinsic discount
US$23.00
Fair Value
Price US$20.36
AnalystLowTarget US$23.00
AnalystConsensusTarget US$24.93
AnalystHighTarget US$31.60

SIBN Community Narratives

AnalystLowTarget·
Fair Value US$23 11.5% undervalued intrinsic discount

Rising US Reimbursement Risk Will Curb Opportunities Yet Allow Recovery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$25 18.6% undervalued intrinsic discount

Expanding Minimally Invasive Procedures Will Open US And European Markets

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystHighTarget·
Fair Value US$31.6 35.6% undervalued intrinsic discount

Aging And Advancing Healthcare Will Expand Minimally Invasive Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$23
11.5% undervalued intrinsic discount
Revenue
15.18% p.a.
Profit Margin
12.91%
Future PE
34.67x
Price in 2028
US$28.58
US$31.6
35.6% undervalued intrinsic discount
Revenue
16.27% p.a.
Profit Margin
12.32%
Future PE
50.33x
Price in 2028
US$38.46
US$25
18.6% undervalued intrinsic discount
Revenue
14.8% p.a.
Profit Margin
12.49%
Future PE
40.89x
Price in 2028
US$30.49

Trending Discussion

Updated Narratives

SIBN logo

SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside

Fair Value: US$23 11.5% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SIBN logo

Aging And Advancing Healthcare Will Expand Minimally Invasive Markets

Fair Value: US$31.6 35.6% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SIBN logo

Expanding Minimally Invasive Procedures Will Open US And European Markets

Fair Value: US$25 18.6% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

2 Risks
3 Rewards

SI-BONE, Inc. Key Details

US$193.6m

Revenue

US$39.5m

Cost of Revenue

US$154.1m

Gross Profit

US$175.9m

Other Expenses

-US$21.8m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.50
79.62%
-11.24%
20.6%
View Full Analysis

About SIBN

Founded
2008
Employees
349
CEO
Laura Francis
WebsiteView website
si-bone.com

SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.